Cathelijne J M Alleman1, Kirsten Y Westerhout2, Marja Hensen2, Colette Chambers3, Malcolm Stoker4, Stephen Long5, Floortje E van Nooten4. 1. Pharmerit B.V., Marten Meesweg 107, Rotterdam, The Netherlands. Electronic address: calleman@pharmerit.com. 2. Pharmerit B.V., Marten Meesweg 107, Rotterdam, The Netherlands. 3. Astellas Pharma Europe Ltd., Chertsey, United Kingdom. 4. Astellas Pharma Europe B.V., Leiden, The Netherlands. 5. INC research Ltd., Surrey, United Kingdom.
Abstract
AIMS: Painful diabetic peripheral neuropathy (PDPN) is a common complication of diabetes mellitus. A systematic literature review was conducted to provide an overview of published literature in the last 10-years on the epidemiology, humanistic burden and economic burden of PDPN in Europe. METHODS: A search was performed according to pre-defined strategy and review criteria in Embase, Pubmed, and conference proceedings databases from 2003 till December 2012. In total, 30 publications written in English covering the relevant patient population and topics of interest. RESULTS: European prevalence ranges from 6% to 34% in diabetes mellitus patients. PDPN has a significant humanistic and economic impact. Patients are limited in their general functioning and their ability to sleep and often experience anxiety and depression. Not surprisingly, PDPN is associated with reduced Health-Related-Quality-of-Life (HRQoL). PDPN patients incur high health care costs due to hospitalizations and outpatient visits. In addition, the painful symptoms cause impaired work productivity. Studies suggest both humanistic and economic burden increase with higher pain severity. CONCLUSIONS: The burden from PDPN appears to be higher with increasing pain severity. More severe pain leads to a higher impairment in daily functioning, sleep and HRQoL. Higher pain intensity also leads to increasing healthcare costs and work productivity losses.
AIMS: Painful diabetic peripheral neuropathy (PDPN) is a common complication of diabetes mellitus. A systematic literature review was conducted to provide an overview of published literature in the last 10-years on the epidemiology, humanistic burden and economic burden of PDPN in Europe. METHODS: A search was performed according to pre-defined strategy and review criteria in Embase, Pubmed, and conference proceedings databases from 2003 till December 2012. In total, 30 publications written in English covering the relevant patient population and topics of interest. RESULTS: European prevalence ranges from 6% to 34% in diabetes mellituspatients. PDPN has a significant humanistic and economic impact. Patients are limited in their general functioning and their ability to sleep and often experience anxiety and depression. Not surprisingly, PDPN is associated with reduced Health-Related-Quality-of-Life (HRQoL). PDPN patients incur high health care costs due to hospitalizations and outpatient visits. In addition, the painful symptoms cause impaired work productivity. Studies suggest both humanistic and economic burden increase with higher pain severity. CONCLUSIONS: The burden from PDPN appears to be higher with increasing pain severity. More severe pain leads to a higher impairment in daily functioning, sleep and HRQoL. Higher pain intensity also leads to increasing healthcare costs and work productivity losses.
Authors: Michael D Staudt; Tarun Prabhala; Breanna L Sheldon; Nicholas Quaranta; Michael Zakher; Ravneet Bhullar; Julie G Pilitsis; Charles E Argoff Journal: J Diabetes Sci Technol Date: 2020-08-28
Authors: Jeffrey L Chen; Andrew W Hesseltine; Sara E Nashi; Shawn M Sills; Tory L McJunkin; Sandeep Patil; Manish Bharara; David L Caraway; Elizabeth S Brooks Journal: J Diabetes Sci Technol Date: 2021-11-29
Authors: Johann M E Jende; Christoph Mooshage; Zoltan Kender; Lukas Schimpfle; Alexander Juerchott; Sabine Heiland; Peter Nawroth; Martin Bendszus; Stefan Kopf; Felix T Kurz Journal: Ann Clin Transl Neurol Date: 2022-04-30 Impact factor: 5.430
Authors: Anna Rydén; Elisabeth Sörstadius; Klas Bergenheim; Alexandru Romanovschi; Fredrik Thorén; Edward A Witt; Catarina Sternhufvud Journal: PLoS One Date: 2016-11-03 Impact factor: 3.240